HRP20120170T1 - Nova upotreba u terapiji kod liječenja leukemije - Google Patents
Nova upotreba u terapiji kod liječenja leukemije Download PDFInfo
- Publication number
- HRP20120170T1 HRP20120170T1 HR20120170T HRP20120170T HRP20120170T1 HR P20120170 T1 HRP20120170 T1 HR P20120170T1 HR 20120170 T HR20120170 T HR 20120170T HR P20120170 T HRP20120170 T HR P20120170T HR P20120170 T1 HRP20120170 T1 HR P20120170T1
- Authority
- HR
- Croatia
- Prior art keywords
- intended
- compound
- administration
- accordance
- followed
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title claims 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 238000007912 intraperitoneal administration Methods 0.000 claims abstract 8
- 238000001990 intravenous administration Methods 0.000 claims abstract 8
- 208000025113 myeloid leukemia Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 229960000975 daunorubicin Drugs 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- -1 2,6-dichlorophenyl Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0611492A FR2910813B1 (fr) | 2006-12-28 | 2006-12-28 | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| PCT/FR2007/002171 WO2008102075A2 (fr) | 2006-12-28 | 2007-12-27 | Nouvelle utilisation therapeutique pour le traitement des leucemies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120170T1 true HRP20120170T1 (hr) | 2012-03-31 |
Family
ID=38268928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120170T HRP20120170T1 (hr) | 2006-12-28 | 2012-02-21 | Nova upotreba u terapiji kod liječenja leukemije |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US8236811B2 (da) |
| EP (1) | EP2107906B1 (da) |
| JP (1) | JP5317987B2 (da) |
| KR (1) | KR101458233B1 (da) |
| CN (1) | CN101568338B (da) |
| AR (1) | AR064550A1 (da) |
| AT (1) | ATE534392T1 (da) |
| AU (1) | AU2007347370B2 (da) |
| BR (1) | BRPI0720963A2 (da) |
| CA (1) | CA2672716C (da) |
| CL (1) | CL2007003846A1 (da) |
| CO (1) | CO6190610A2 (da) |
| CR (1) | CR10881A (da) |
| CY (1) | CY1112443T1 (da) |
| DK (1) | DK2107906T3 (da) |
| EA (1) | EA016873B1 (da) |
| EC (1) | ECSP099449A (da) |
| ES (1) | ES2377843T3 (da) |
| FR (1) | FR2910813B1 (da) |
| GT (1) | GT200900168A (da) |
| HK (1) | HK1138189A1 (da) |
| HR (1) | HRP20120170T1 (da) |
| JO (1) | JO2748B1 (da) |
| MA (1) | MA31100B1 (da) |
| MX (1) | MX2009007054A (da) |
| MY (1) | MY148515A (da) |
| NI (1) | NI200900129A (da) |
| NO (1) | NO20092496L (da) |
| NZ (1) | NZ577991A (da) |
| PE (1) | PE20081548A1 (da) |
| PL (1) | PL2107906T3 (da) |
| PT (1) | PT2107906E (da) |
| RS (1) | RS52162B (da) |
| SI (1) | SI2107906T1 (da) |
| SV (1) | SV2009003315A (da) |
| TN (1) | TN2009000234A1 (da) |
| TW (1) | TWI433678B (da) |
| UA (1) | UA97505C2 (da) |
| WO (1) | WO2008102075A2 (da) |
| ZA (1) | ZA200904478B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2948568B1 (fr) | 2009-07-30 | 2012-08-24 | Sanofi Aventis | Formulation pharmaceutique |
| EP2638911A1 (en) | 2012-03-14 | 2013-09-18 | Sanofi | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
| AR098716A1 (es) * | 2013-12-13 | 2016-06-08 | Novartis Ag | Formas de dosificación farmacéuticas |
| US20230136218A1 (en) * | 2019-09-23 | 2023-05-04 | President And Fellows Of Harvard College | Methods and compositions for treating acute myeloid leukemia |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1171218A (en) | 1967-11-09 | 1969-11-19 | Parke Davis & Co | New Heterocyclic Amine Compounds and Methods for their Production |
| EP0790997B1 (en) | 1994-11-14 | 2000-03-22 | Warner-Lambert Company | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION |
| IL115256A0 (en) | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| AU7315700A (en) | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
| AP2002002586A0 (en) | 2000-01-25 | 2002-09-30 | Warner Lambert Co | Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. |
| IL151480A0 (en) | 2000-03-06 | 2003-04-10 | Warner Lambert Co | 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors |
| EP1307450B1 (en) | 2000-08-04 | 2008-09-17 | Warner-Lambert Company LLC | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones |
| US20030105115A1 (en) * | 2001-06-21 | 2003-06-05 | Metcalf Chester A. | Novel pyridopyrimidines and uses thereof |
| WO2004063195A1 (en) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| UY29017A1 (es) | 2004-07-16 | 2006-02-24 | Boehringer Ingelheim Int | Inhibidores de polimerasa viral |
| FR2887882B1 (fr) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
-
2006
- 2006-12-28 FR FR0611492A patent/FR2910813B1/fr not_active Expired - Fee Related
-
2007
- 2007-12-24 TW TW096149811A patent/TWI433678B/zh not_active IP Right Cessation
- 2007-12-27 AU AU2007347370A patent/AU2007347370B2/en not_active Ceased
- 2007-12-27 CA CA2672716A patent/CA2672716C/fr not_active Expired - Fee Related
- 2007-12-27 SI SI200730860T patent/SI2107906T1/sl unknown
- 2007-12-27 UA UAA200907941A patent/UA97505C2/ru unknown
- 2007-12-27 BR BRPI0720963-0A patent/BRPI0720963A2/pt active Search and Examination
- 2007-12-27 NZ NZ577991A patent/NZ577991A/en not_active IP Right Cessation
- 2007-12-27 AR ARP070105919A patent/AR064550A1/es not_active Application Discontinuation
- 2007-12-27 EP EP07872446A patent/EP2107906B1/fr active Active
- 2007-12-27 EA EA200970639A patent/EA016873B1/ru not_active IP Right Cessation
- 2007-12-27 ZA ZA200904478A patent/ZA200904478B/xx unknown
- 2007-12-27 PL PL07872446T patent/PL2107906T3/pl unknown
- 2007-12-27 AT AT07872446T patent/ATE534392T1/de active
- 2007-12-27 MX MX2009007054A patent/MX2009007054A/es active IP Right Grant
- 2007-12-27 PT PT07872446T patent/PT2107906E/pt unknown
- 2007-12-27 JP JP2009543501A patent/JP5317987B2/ja not_active Expired - Fee Related
- 2007-12-27 CN CN2007800482286A patent/CN101568338B/zh not_active Expired - Fee Related
- 2007-12-27 WO PCT/FR2007/002171 patent/WO2008102075A2/fr active Application Filing
- 2007-12-27 ES ES07872446T patent/ES2377843T3/es active Active
- 2007-12-27 CL CL2007003846A patent/CL2007003846A1/es unknown
- 2007-12-27 MY MYPI20092747A patent/MY148515A/en unknown
- 2007-12-27 RS RS20120061A patent/RS52162B/en unknown
- 2007-12-27 JO JO2007563A patent/JO2748B1/en active
- 2007-12-27 KR KR1020097013456A patent/KR101458233B1/ko not_active IP Right Cessation
- 2007-12-27 DK DK07872446.5T patent/DK2107906T3/da active
-
2008
- 2008-01-02 PE PE2008000043A patent/PE20081548A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 TN TNP2009000234A patent/TN2009000234A1/fr unknown
- 2009-06-16 US US12/485,401 patent/US8236811B2/en not_active Expired - Fee Related
- 2009-06-16 GT GT200900168A patent/GT200900168A/es unknown
- 2009-06-22 EC EC2009009449A patent/ECSP099449A/es unknown
- 2009-06-22 CR CR10881A patent/CR10881A/es not_active Application Discontinuation
- 2009-06-24 SV SV2009003315A patent/SV2009003315A/es active IP Right Grant
- 2009-06-26 NI NI200900129A patent/NI200900129A/es unknown
- 2009-06-26 CO CO09066898A patent/CO6190610A2/es active IP Right Grant
- 2009-07-02 NO NO20092496A patent/NO20092496L/no not_active Application Discontinuation
- 2009-07-16 MA MA32101A patent/MA31100B1/fr unknown
-
2010
- 2010-04-14 HK HK10103640.6A patent/HK1138189A1/xx not_active IP Right Cessation
-
2012
- 2012-02-21 HR HR20120170T patent/HRP20120170T1/hr unknown
- 2012-02-23 CY CY20121100183T patent/CY1112443T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
| HRP20110451T1 (hr) | Upotreba izotiocijanata kao sredstva protiv mieloma | |
| AR057295A1 (es) | Combinaciones y procedimientos para usar un compuestos de indolinona | |
| ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
| MY145647A (en) | (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states) | |
| BRPI0408236A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
| MY148571A (en) | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines | |
| CY1108690T1 (el) | Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων | |
| ES2422557T3 (es) | Compuestos y composiciones como moduladores de la ruta Hedgehog | |
| MY150717A (en) | Long term treatment of hiv-infection with tmc278 | |
| TW200716204A (en) | Pharmaceutical composition | |
| MX2022016405A (es) | Análogos de nucleósido de 1¿-ciano y usos de estos. | |
| HRP20120170T1 (hr) | Nova upotreba u terapiji kod liječenja leukemije | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| HK1176318A1 (en) | Injection device | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| CY1109743T1 (el) | Παραγωγα των 2-βενζοϋλο-ιμιδαζοπυριδινων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη | |
| NZ705849A (en) | Tetracycline compounds | |
| MX2009006574A (es) | Tratamiento de cancer de pulmon. | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| MX2009006325A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| MX2007009312A (es) | Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables. | |
| AR063140A1 (es) | Nuevo peptido de actinomadura nambiensis | |
| WO2007081540A3 (en) | Tylophorine analogs as antitumor agents |